Abiopharma

🔍 Collins Kathryn M (Executive)

Company: Frontdoor, Inc. (FTDR)

Report Date: 2026-03-30

Detailed Transactions and Holdings:

• Acquired 6,574 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: M | equity_swap_involved: false | shares_owned_after: 23,276.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,954 shares of Common Stock at $51.95 per share (Direct)
  Date: 2026-03-31 | Code: F | equity_swap_involved: false | shares_owned_after: 20,322.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 14,914 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-30 | Code: A | equity_swap_involved: false | shares_owned_after: 14,914.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Sold 6,574 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-31 | Code: M | equity_swap_involved: false | shares_owned_after: 13,147.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Reflects restricted stock units that upon vesting convert into shares of common stock on a one-for-one basis.
• F2: Reflects shares withheld to cover the Reporting Person's tax liability incident to the vesting of restricted stock units.
• F3: Each unit is the economic equivalent of one share of the Company's stock. The restricted stock units were granted on March 30, 2026 and will vest and settle in three equal installments on March 30, 2027, 2028 and 2029, subject to continued service with the Company.
• F4: Each unit is the economic equivalent of one share of the Company's stock. The restricted stock units were granted on March 31, 2025 and will vest and settle in three equal installments on March 31, 2026, 2027 and 2028, subject to continued service with the Company.